Compare Dicks Sporting Goods Inc (DKS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Novartis AG — how do they compare? Dicks Sporting Goods Inc trades at $134.34 (market cap $13.26B), while Novartis AG trades at $142.98 (market cap $268.57B). The key difference: Novartis AG is far larger — about 20.3× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Novartis AG for 82 Days on average.
| DKS | NVS | |
|---|---|---|
Market Cap | $13.26B | $268.57B |
Volume | 2,292,035 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $168.62 |
52-Week Low | $121.15 | $121.80 |
Typical Hold Time | 19 Days | 82 Days |
Enterprise Value | $20.31B | $309.89B |
Dividend Yield | 3.71% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, amid a bearish technical signal and ongoing securities class action news. The stock shows mixed fundamentals with a trailing P/E of 14.86 and P/S of 0.57, while recent earnings beat estimates in two of the last three quarters. Revenue grew to $13.44B in 2025, though net income margin compressed to 3.97% in 2026 trends. Analyst consensus remains positive with a $153.30 price target and 57% buy ratings, but legal overhangs and a negative cash flow trend present headwinds.
The investment case balances attractive valuation multiples against significant litigation risks and weakening profitability. Upside exists if the company navigates legal challenges and stabilizes margins, but the bearish technical setup and negative investor sentiment suggest caution. The stock's near-term direction will likely hinge on Q3 2026 earnings results and developments in the class action lawsuit.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
